

EDITORIAL

Current Status of Medical Biotechnology in Malaysia

J.W. Mak, MRCPath

Institute of Medical Research, Jalan Pahang, Kuala Lumpur

B.A.K. Khalid, FRACP

Faculty of Medicine, Universiti Kebangsaan Malaysia, Jalan Raja Abdul Aziz, Kuala Lumpur

In recent years medical research, utilising biotechnology and related tools, has contributed significantly to advances in the laboratory diagnosis of infectious diseases and hormonal disorders in Malaysia.

The main thrust was in the development of diagnostic assays or kits, either for import substitution or to meet diagnostic needs for diseases of importance. Emphasis was on the development of diagnostic probes either using the hybridoma technology for the production of monoclonal antibodies (MABs) or the development of nucleic acid probes. In other instances, more conventional techniques for the production of polyclonal antibodies and their subsequent radiolabelling for radioimmunoassays were carried out. The applicability of polymerase chain reaction (PCR) in the development of rapid and specific diagnostic assays was investigated.

Examples of research utilising conventional as well as newer techniques were those in viral diseases like dengue, dengue haemorrhagic fever, Japanese B encephalitis, and Hepatitis B virus. A mosquito larva inoculation method was developed and refined for the rapid isolation (4 days) of dengue virus^{1,2}. An IgM capture ELISA using monoclonal antibodies was found to be useful for the early diagnosis of dengue infection³. A similar test using cell culture derived dengue antigens and a polyclonal rabbit anti-flavivirus antisera, and a dot enzyme immunoassay for the detection of dengue were also developed⁴. The former test is useful for the detection of primary infections while the latter can be used to detect secondary infections. Similar IgM capture ELISA and dot blot assays were developed for Japanese B encephalitis infection^{5,6}. An in-house assay based on a modified double sandwich ELISA was also developed for the detection of HBsAg⁷.

In bacterial diseases, typhoid and other salmonellosis were studied. A dot blot ELISA based on a specific 50 kDa outer membrane protein of *Salmonella typhi* was developed for the detection of specific IgM and IgG antibodies for the rapid diagnosis of typhoid⁸.

For parasitic infections, malaria, filariasis, toxoplasmosis, toxocariasis and angiostrongyliasis were studied. The emphasis was to develop immunodiagnostic assays for patient diagnosis and epidemiological assessment. Most of these immunodiagnostic assays are not commercially available (angiostrongyliasis, filariasis, toxocariasis) or extremely expensive (toxoplasmosis, malaria). The indirect fluorescent antibody assay (IFA) for the diagnosis of filariasis, malaria and toxoplasmosis and the ELISA for toxocariasis were developed and are routinely being used⁹. ELISA assays based on various stage-specific antigens were also developed for seroepidemiological assessment of malaria endemicities^{9,10}.

Immunodiagnostic assays for thyroid and other hormonal disorders, including diabetes, were also developed. A dot enzyme immunoassay for simultaneous measurements of autoantibodies against thyroglobulin and thyroid microsomes, which does not require any sophisticated equipment, was developed¹¹. This was complemented later with an ELISA for thyroid autoantibodies. At the same time, a sensitive ELISA for thyroid stimulating hormone (TSH) useful for diagnostic and epidemiological studies was also developed¹². Highly sensitive radioimmunoassays for various steroid hormones were also developed and used locally¹³. A cortisol assay which measures salivary cortisol and therefore approximates free cortisol levels was a useful development¹⁴. Non-isotopic ELISA were also developed for pituitary peptide hormones using polyclonal and monoclonal antibodies¹⁵, as an alternative to RIAs and IRMAs for these peptides¹⁶. Assays were also developed to overcome problems of transport of specimens such as blood or sera. A glycosylated haemoglobin measurement by filter paper microcolorimetric method was the first to be tried¹⁷ and further refined¹⁸. With these methods of sample collection and storage, epidemiological studies in difficult terrain could be achieved¹⁹.

The necessity to produce diagnostic reagents of defined specificity and sensitivity cannot be overemphasised. Some reagents are easily available through *in vivo* replication in animal models or *in vitro* culture of the disease agent. Others are difficult to produce using these conventional techniques and in these instances, recombinant DNA techniques for the production of DNA probes, or where appropriate, production of fusion proteins or oligopeptides using the pin technology of Geysen²⁰ is applicable. The latter allows the production not only of defined oligopeptides but also minotopes that can mimic antigenic epitopes of disease agents recognised by the immune system¹.

The future emphasis will be the application of newer tools like the PCR amplification of nucleic acid for increased sensitivity in diagnosis. Examples of the potential use of this technique in infectious diseases will be in the rapid diagnosis and serotyping of dengue infections. Another example will be its use in confirming infection with RI resistant strains of *Plasmodium falciparum* parasites to antimalarials, where a negative result on microscopy at the first post-treatment week, may actually be false and parasites may in fact be detectable after amplification of parasite DNA. In this connection DNA probes for *P. falciparum* are already available and with the development of more sensitive non-radioisotope labelling techniques, the practical use of such nucleic acid probes in many clinical laboratories is a distinct possibility.

Another area of intense research in the next couple of years will be the production of recombinant proteins such as diagnostic reagents. Currently this is being carried out for Japanese B encephalitis, dengue, toxocarasis, toxoplasmosis, malaria, filariasis and other infectious diseases in a number of laboratories. Some of these have been produced and are currently being tested for use in diagnosis. With the complementary use of MABs, more specific diagnostic assays to detect antigens and antibodies will be available not only for diagnosis at the patient level but also for seroepidemiological studies to evaluate disease endemicity and the effectiveness of control programmes.

The emphasis on the development of diagnostic assays for the above disease needs no apology, for it addresses the direct needs of the Ministry of Health in the provision of health care to the population. Research funding from the Ministry of Science, Technology and Environment, Malaysia, through the Intensification in Priority Areas (IRPA) mechanism, was extremely generous during the last few years and was directly or indirectly responsible for the successful development of a range of diagnostic tests which are currently being utilised for patient management and control programme purposes. Although continued funding for such research will be vital, researchers in Malaysia must utilise fully the potential power of the new tools of molecular biology for medical research. In particular, more medically qualified personnel must be trained in these areas and encouraged to carry out such research.

References

1. Pang T, Lam SK, Chew CB, Poon GK, Ramalingam S. Isolation of dengue viruses by intracerebral inoculation of mosquito larvae. *Lancet* 1983;i : 1271.
2. Chew CB, Paul V, Teo L, Poon GK, Lam SK. A comparative study in the isolation of dengue viruses by inoculation of mosquito larvae and mosquito cell line. *Malaysian J Med Lab Scs* 1988;5 : 23-4.
3. Lam SK, Devi S, Pang T. Detection of specific IgM in dengue infection. *Southeast Asian J Trop Med Pub Hlth* 1987;18 : 532-8.
4. Cardoso MJ, Zuraini I. Comparison of an IgM capture ELISA with a dot enzyme immunoassay for laboratory diagnosis of dengue virus infection. *Southeast Asian J Trop Med Pub Hlth* 1991;22 : 337-40.
5. Cardoso MJ, Choo BH, Zuraini I. A serological study of Japanese encephalitis virus infections in Northern Peninsular Malaysia. *Southeast Asian J Trop Med Pub Hlth* 1991;22 : 341-6.
6. Cardoso MJ, Tan HS, Zuraini I, Tio PH. Use of a dot immunoassay for determination of antibodies to a multianalyte panel: applications for rapid screening of population for antibody profiles. *Trop Biomed* 1992;8 : 151-6.
7. Yap KL, Mooi KC. Development of an ELISA for HBsAg detection. Seminar Program Bioteknologi Kebangsaan Ke-III, 27-29 Oktober 1991, Kuantan, Pahang, Abstrak No.51.
8. Ismail A, Kader ZSA, Ong KH. Dot enzyme immunosorbent assay for the serodiagnosis of typhoid fever. *Southeast Asian J Trop Med Pub Hlth* 1991;22 : 563-6.
9. Mak JW. Review of seroepidemiological tools for control programme of parasitic diseases in Malaysia. *Trop Biomed* 1988;5 : 28-32.
10. Mak JW, Lim PKC, Lam PLW, Noor Rain A, Selvadurai GD, Hanjeet K. Parasitological and serological surveys for malaria among the inhabitants of an aborigine village and an adjacent Malay village. *Acta Tropica* 1987;44 : 83-9.
11. Ng ML, Rajna A, Khalid BAK. Enzyme immunoassay for the simultaneous measurement of autoantibodies against thyroglobulin and thyroid microsomes. *Clin Chem* 1987;33 : 2287-8.
12. Goh KH, Ng ML, Thean ETT, Khalid BAK. A supersensitive in-house enzyme-linked immunosorbent assay (ELISA) for measurement of thyroid stimulating hormone and its clinical applications. *Med J Malaysia* 1992;47 : 249-61.
13. Khalid BAK, Ng ML, Wan Zurinah WN, Lui SK, Goh KH, Lo MS. Development and production of cheap and simple hormone measurements using RIA and ELISA. In: *Prioriti Penyelidikan* (eds). Zakri Hamid, Ismail Sahid, Md Noor Embi. Universiti Kebangsaan Malaysia Press 1991;Pp : 162-7.
14. Lo MSI, Ng ML, Azmy BS, Khalid BAK. Clinical applications of salivary cortisol measurements. *Singapore Med J* 1992;33 : 170-3.
15. Ng ML, Goh KH, Wan Nazaimoon WM, Thean ETT, Khalid BAK. Non isotopic in-house ELISA as alternative to RIA/IRMA for measurement of pituitary peptide hormones. In: *IAEA/WHO International Symposium on RIA, Vienna, Austria*. 1991;Pp : 515-22.
16. Wan Nazaimoon WM, Ng ML, Satgunasingam N, Khalid BAK. Development of an in-house radioimmunoassay for human growth hormone. *Mal J Pathol* 1990;12 : 13-20.
17. Ng ML, Sazali BS, Khalid BAK. Glucosylated haemoglobin measurement by a microcolorimetric method. *J ASEAN Fed Endocr Soc* 1986;5 : 33-7.
18. Ng ML, Sazali BS, Khalid BAK. Collection and storage of capillary blood in glass fibre filters for glycosylated haemoglobin measurement by a microcolorimetric method. *Annals Clin Chem* 1991;28 : 613-7.
19. Osman Ali, Tan TT, Sakinah SO, Ng ML, Khalid BAK. The prevalence of diabetes mellitus and impaired glucose tolerance in aborigines and Malays and its relationship to socio-demographic, health and nutritional factors. *Diabetes Care* 1992 (in press).
20. Geysen HM, Meleon RH, Barteling SJ. Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid. *Proc Natl Acad Sci USA* 1984;81 : 3998-4002.